Monoclonal antibody treatment of RSV bronchiolitis in young infants: A randomized trial

Pediatrics

Volumn 143, Issue 3, 2019, Pages

  Alansari, Khalid ^a,b,c   Toaimah, Fatihi Hassan ^a   Almatar, Daher Helmi ^a   El Tatawy, Daher Helmi ^a   Davidson, Bruce L ^d   Qusad, Mohammad Ibrahim Mohammad ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^c Department of Obstetrics Gynecology   (Qatar)

^d St John Providence Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PEDIATRIC INTENSIVE CARE UNIT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; TREATMENT OUTCOME; VIRAL BRONCHIOLITIS; BRONCHIOLITIS; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; NEWBORN;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; MALE; PALIVIZUMAB; PATIENT READMISSION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 85062765330     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2018-2308     Document Type: Article

References (30)

1. Meissner HC. Viral bronchiolitis in children. N Engl J Med. 2016; 374 (1): 62-72
2. Petruzella FD, Gorelick MH. Duration of illness in infants with bronchiolitis evaluated in the emergency department. Pediatrics. 2010; 126 (2): 285-290
3. Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H, Ibrahim K. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr. 2010; 157 (4): 630-634, 634.e1
4. Alansari K, Sakran M, Davidson BL, Ibrahim K, Alrefai M, Zakaria I. Oral dexamethasone for bronchiolitis: a randomized trial. Pediatrics. 2013; 132 (4). Available at: www.pediatrics. Org/cgi/content/full/132/4/e810
5. Sandweiss DR, Mundorff MB, Hill T, et al. Decreasing hospital length of stay for bronchiolitis by using an observation unit and home oxygen therapy. JAMA Pediatr. 2013; 167 (5): 422-428
6. Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014; 134 (5). Available at: www.pediatrics.org/cgi/content/full/134/5/e1474
7. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. J Perinatol. 2016; 36 (11): 990-996
8. Jepsen MT, Trebbien R, Emborg HD, et al. Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015. Euro Surveill. 2018; 23 (3)
9. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011; 162 (1-2): 80-99
10. Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases-borrowing from history. N Engl J Med. 2018; 378 (16): 1469-1472
11. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008; 317: 103-123
12. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102 (3): 531-537
13. Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr. 2010; 6 (4): 296-300
14. Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis. 1992; 145 (1): 106-109
15. Plint AC, Taljaard M, McGahern C, et al. Management of bronchiolitis in community hospitals in Ontario: a multicentre cohort study. CJEM. 2016; 18 (6): 443-452
16. Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 1997; 100 (6): 937-942
17. Rodriguez WJ, Gruber WC, Welliver RC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 1997; 99 (3): 454-461
18. Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998; 178 (6): 1555-1561
19. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001; 184 (3): 350-354
20. Banna GL, Aversa SM, Cattelan AM, Crivellari G, Monfardini S. Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy. Scand J Infect Dis. 2004; 36 (2): 155-157
21. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J. 2007; 26 (12): 1089-1093
22. Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010; 12 (1): 38-44
23. McCoy D, Wong E, Kuyumjian AG, Wynd MA, Sebti R, Munk GB. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institutionspecific guideline. Transpl Infect Dis. 2011; 13 (2): 117-121
24. Shachor-Meyouhas Y, Zaidman I, Kra-Oz Z, Arad-Cohen N, Kassis I. Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department. J Pediatr Hematol Oncol. 2013; 35 (2): 124-128
25. Helmink BJ, Ragsdale CE, Peterson EJ, Merkel KG. Comparison of intravenous palivizumab and standard of care for treatment of respiratory syncytial virus infection in mechanically ventilated pediatric patients. J Pediatr Pharmacol Ther. 2016; 21 (2): 146-154
26. Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH Jr, Connor EM; MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004; 23 (8): 707-712
27. Ramilo O, Lagos R, Sáez-Llorens X, et al; Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014; 33 (7): 703-709
28. Miyairi I, DeVincenzo JP. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev. 2008; 21 (4): 686-703
29. van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol. 2012; 2 (3): 300-305
30. McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis. 2005; 191 (8): 1225-1232